160 related articles for article (PubMed ID: 31121192)
1. CDX2 and Muc2 immunohistochemistry as prognostic markers in stage II colon cancer.
Cecchini MJ; Walsh JC; Parfitt J; Chakrabarti S; Correa RJ; MacKenzie MJ; Driman DK
Hum Pathol; 2019 Aug; 90():70-79. PubMed ID: 31121192
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients.
Ribeirinho-Soares S; Pádua D; Amaral AL; Valentini E; Azevedo D; Marques C; Barros R; Macedo F; Mesquita P; Almeida R
BMC Cancer; 2021 Apr; 21(1):359. PubMed ID: 33823840
[TBL] [Abstract][Full Text] [Related]
3. CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma.
Shin JH; Bae JH; Lee A; Jung CK; Yim HW; Park JS; Lee KY
Jpn J Clin Oncol; 2010 Mar; 40(3):208-13. PubMed ID: 19926591
[TBL] [Abstract][Full Text] [Related]
4. Quantitative analysis of CDX2 protein expression improves its clinical utility as a prognostic biomarker in stage II and III colon cancer.
den Uil SH; de Wit M; Slebos RJC; Delis-van Diemen PM; Sanders J; Piersma SR; Pham TV; Coupé VMH; Bril H; Stockmann HBAC; Jimenez CR; Meijer GA; Fijneman RJA
Eur J Cancer; 2021 Feb; 144():91-100. PubMed ID: 33341450
[TBL] [Abstract][Full Text] [Related]
5. CDX2 Loss With Microsatellite Stable Phenotype Predicts Poor Clinical Outcome in Stage II Colorectal Carcinoma.
Slik K; Turkki R; Carpén O; Kurki S; Korkeila E; Sundström J; Pellinen T
Am J Surg Pathol; 2019 Nov; 43(11):1473-1482. PubMed ID: 31490234
[TBL] [Abstract][Full Text] [Related]
6. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
Dalerba P; Sahoo D; Paik S; Guo X; Yothers G; Song N; Wilcox-Fogel N; Forgó E; Rajendran PS; Miranda SP; Hisamori S; Hutchison J; Kalisky T; Qian D; Wolmark N; Fisher GA; van de Rijn M; Clarke MF
N Engl J Med; 2016 Jan; 374(3):211-22. PubMed ID: 26789870
[TBL] [Abstract][Full Text] [Related]
7. Co-expression of CDX2 and MUC2 in gastric carcinomas: correlations with clinico-pathological parameters and prognosis.
Roessler K; Mönig SP; Schneider PM; Hanisch FG; Landsberg S; Thiele J; Hölscher AH; Dienes HP; Baldus SE
World J Gastroenterol; 2005 Jun; 11(21):3182-8. PubMed ID: 15929165
[TBL] [Abstract][Full Text] [Related]
8. Hierarchical clustering identifies a subgroup of colonic adenocarcinomas expressing crypt-like differentiation markers, associated with MSS status and better prognosis.
Droy-Dupré L; Bossard C; Volteau C; Bezieau S; Laboisse CL; Mosnier JF
Virchows Arch; 2015 Apr; 466(4):383-91. PubMed ID: 25665656
[TBL] [Abstract][Full Text] [Related]
9. Intestinal and pancreatobiliary differentiation in periampullary carcinoma: the role of immunohistochemistry.
Kumari N; Prabha K; Singh RK; Baitha DK; Krishnani N
Hum Pathol; 2013 Oct; 44(10):2213-9. PubMed ID: 23834763
[TBL] [Abstract][Full Text] [Related]
10. The Prognostic Role of Mismatch Repair Status and CDX-2 Expression with Inflammatory Markers and Pathological Risk Factors in Stage II and III Colon Cancer: Multicenter Real-Life Data.
Aydin SG; Olmez OF; Selvi O; Geredeli C; Ozden F; Bilici A; Acikgoz O; Karci E; Kutlu Y; Hamdard J; Aydin A
J Gastrointest Cancer; 2024 Mar; 55(1):227-236. PubMed ID: 37347353
[TBL] [Abstract][Full Text] [Related]
11. Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.
Ben-Aharon I; Goshen-Lago T; Sternschuss M; Morgenstern S; Geva R; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Shulman K; Mishaeli M; Man S; Liebermann N; Soussan-Gutman L; Brenner B
Oncologist; 2019 Aug; 24(8):e696-e701. PubMed ID: 30755502
[TBL] [Abstract][Full Text] [Related]
12. Differential Expression of β-Catenin, EGFR, CK7, CK20, MUC1, MUC2, and CDX2 in Intestinal and Pancreatobiliary-Type Ampullary Carcinomas.
Perysinakis I; Minaidou E; Leontara V; Mantas D; Sotiropoulos GC; Tsipras H; Zografos GN; Margaris I; Kouraklis G
Int J Surg Pathol; 2017 Feb; 25(1):31-40. PubMed ID: 27543509
[TBL] [Abstract][Full Text] [Related]
13. [Combined application of immunohistochemical markers to identify pathologic subtypes of ampullary carcinoma and its clinical significance].
Liu FF; Shen DH; Wang HL; Ma YT; Yuan F; Liu J; Chen L; Song QJ; Zhang YY
Zhonghua Bing Li Xue Za Zhi; 2019 Feb; 48(2):92-97. PubMed ID: 30695858
[No Abstract] [Full Text] [Related]
14. [Expression and clinical significance of Mucin and E-cadherin in colorectal tumors].
Yu XW; Rong W; Xu FL; Xu GY; Sun YR; Feng MY
Ai Zheng; 2007 Nov; 26(11):1204-10. PubMed ID: 17991319
[TBL] [Abstract][Full Text] [Related]
15. CDX2 Protein Expression in Colorectal Cancer and ItsCorrelation with Clinical and Pathological Characteristics, Prognosis, and Survival Rate of Patients.
Asgari-Karchekani S; Karimian M; Mazoochi T; Taheri MA; Khamehchian T
J Gastrointest Cancer; 2020 Sep; 51(3):844-849. PubMed ID: 31630373
[TBL] [Abstract][Full Text] [Related]
16. Combination of CDX2 expression and T stage improves prognostic prediction of colorectal cancer.
Xu W; Zhu Y; Shen W; Ding W; Wu T; Guo Y; Chen X; Zhou M; Chen Y; Cui L; Du P
J Int Med Res; 2019 May; 47(5):1829-1842. PubMed ID: 30616445
[TBL] [Abstract][Full Text] [Related]
17. Concomitant expression patterns of CDX2 and SATB2 as prognostic factors in stage III colorectal cancers.
Lee JA; Park HE; Jin HY; Jin L; Cho NY; Bae JM; Kim JH; Kang GH
Ann Diagn Pathol; 2024 Aug; 71():152289. PubMed ID: 38555678
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of CDX2 and Villin Expression in Advanced Stage Colorectal Carcinoma.
Altintas S; Bayrak M; Altintas Y
J Coll Physicians Surg Pak; 2019 Nov; 29(11):1057-1061. PubMed ID: 31659962
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of CDX2 in stage II colon cancer: results from two nationwide cohorts.
Hansen TF; Kjær-Frifeldt S; Eriksen AC; Lindebjerg J; Jensen LH; Sørensen FB; Jakobsen A
Br J Cancer; 2018 Nov; 119(11):1367-1373. PubMed ID: 30425348
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical molecular phenotypes of gastric cancer based on SOX2 and CDX2 predict patient outcome.
Camilo V; Barros R; Celestino R; Castro P; Vieira J; Teixeira MR; Carneiro F; Pinto-de-Sousa J; David L; Almeida R
BMC Cancer; 2014 Oct; 14():753. PubMed ID: 25300947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]